{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:56:49Z","timestamp":1795085809435,"version":"4.10.2"},"reference-count":31,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational \u2018real-world\u2019 retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs. Results: 165 patients were analyzed: 62.4% males; 8.5% with a prior cancer; 113 with solid SPMs, mainly \u2265stage 2; and 52 with hematological SPM (hemato-SPM), mainly MDS\/AML. Patients with hemato-SPM were younger (p = 0.05) and more frequently had a prior AutoHCT (p = 0.012). The time to SPM was shorter in the older (&gt;65 years) and more heavily pretreated patients. One hundred patients were actively treated at the time of SPM detection. Treatment was discontinued in 52, substituted with another anti-MM therapy in 15, and continued in 33 patients. Treatment discontinuation was predominant in the patients diagnosed with hemato-SPM (76%). The median OS following SPM detection was 8.5 months, and the main cause of death was SPM. A poor ECOG status predicted a shorter OS (PS 3 vs. 0, HR = 5.74, 2.32\u201314.21, p &lt; 0.001), whereas a normal hemoglobin level (HR = 0.43, 0.19\u20130.95, p = 0.037) predicted longer OS. Conclusions: With the continuing improvement in OS, a higher proportion of MM patients might develop SPM. The OS following SPM diagnosis is poor; hence, frequent surveillance and early detection are imperative to improve outcomes.<\/jats:p>","DOI":"10.3390\/cancers15174359","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:45:31Z","timestamp":1693557931000},"page":"4359","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients"],"prefix":"10.3390","volume":"15","author":[{"given":"Irit","family":"Avivi","sequence":"first","affiliation":[{"name":"Department of Hematology, Tel Aviv Sourasky Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, New Jersey Medical School, Rutgers University, Hackensack, NJ 07601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-2073","authenticated-orcid":false,"given":"Julio","family":"Davila-Valls","sequence":"additional","affiliation":[{"name":"Hospital Nuestra Se\u00f1ora de Sonsoles, 05004 \u00c1vila, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Usnarska-Zubkiewicz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Olszewska-Szopa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-6688","authenticated-orcid":false,"given":"Vibor","family":"Milunovic","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-5844","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Baumert","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogumi\u0142a","family":"Os\u0119kowska","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kopi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit AO of Cosenza, Cosenza and Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Puertas-Martinez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, 90-752 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4731","authenticated-orcid":false,"given":"Edvan","family":"Crusoe","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia, Hospital Universit\u00e1rio Professor Edgar Santos, Servi\u00e7o de Hematologia, Salvador 40110-909, BA, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodriguez-Lobato","sequence":"additional","affiliation":[{"name":"Amyloidosis and Multiple Myeloma Unit, Department of Hematology, Hospital Cl\u00ednic of Barcelona, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-4042","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Gajewska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Military Institute of Medicine, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-056X","authenticated-orcid":false,"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"University Hospitals (UZ) Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tel Aviv Sourasky Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-6891","authenticated-orcid":false,"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-2077","authenticated-orcid":false,"given":"Camila","family":"Pena","sequence":"additional","affiliation":[{"name":"Secci\u00f3n Hematolog\u00eda, Hospital del Salvador, Santiago 13123, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Shustik","sequence":"additional","affiliation":[{"name":"Royal Victoria Hospital, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-7398","authenticated-orcid":false,"given":"Gabor","family":"Mikala","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, National Institute for Hematology and Infectious Diseases, South Pest Central Hospital, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-1195","authenticated-orcid":false,"given":"Klara","family":"Zalac","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinics for Internal Medicine, University Hospital Center \u201cSestre Milosrdnice\u201d, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Denis","family":"Alexander","sequence":"additional","affiliation":[{"name":"Personalised Medicine Centre, School of Medicine, Ulster University, Derry\/Londonderry BT47 6SB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical-Center Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Nieves Lopez-Mu\u00f1oz Hospital, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-1750","authenticated-orcid":false,"given":"Anna","family":"Waszczuk-Gajda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Diseases, Warsaw Medical University, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Krzysta\u0144ski","sequence":"additional","affiliation":[{"name":"Independent IT Specialist, 31-864 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jagiellonian University Medical College, 31-155 Crakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-022-00640-6","article-title":"Increased mortality risk in multiple-myeloma patients with subsequent malignancies: A population-based study in the Netherlands","volume":"12","author":"Brink","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101144","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbmt.2012.09.023","article-title":"Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma","volume":"19","author":"Krishnan","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: An overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","article-title":"Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients","volume":"11","author":"Rosenberg","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: The (r)evolution of current therapy and a glance into the future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Finkelstein, D.M., Horick, N.K., Ramchandani, R., Boyd, K.L., Rana, H.Q., and Bychkovsky, B.L. (2019). Are rare cancer survivors at elevated risk of subsequent new cancers?. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5358-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.21037\/atm-20-2059","article-title":"Multidisciplinary Oncology Research Collaborative Group (MORCG). Second primary malignancies among cancer patients","volume":"8","author":"Zheng","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14393","DOI":"10.1038\/s41598-020-71243-z","article-title":"Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.3324\/haematol.2015.134049","article-title":"Survival in multiple myeloma patients who develop second malignancies: A population-based cohort study","volume":"101","author":"Jonsdottir","year":"2016","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: Is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ejh.13650","article-title":"Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma","volume":"107","author":"Jonsdottir","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00277-022-04806-x","article-title":"The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation","volume":"101","author":"Gramegna","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood.V108.11.5329.5329","article-title":"Myelodysplasia after Autologous Stem Cell Transplantation for Multiple Myeloma","volume":"108","author":"Franz","year":"2006","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., Garcia-Sanz Ramon Mateos, M.V., Garayoa, M., and Paino, T. (2021). Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers, 13.","DOI":"10.3390\/cancers13061353"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2040620719854171","DOI":"10.1177\/2040620719854171","article-title":"Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma","volume":"10","author":"Swan","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, J., Lv, C., Zhou, M., Xu, J.Y., Chen, B., and Wan, Y. (2022). Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018. Cancers, 14.","DOI":"10.3390\/cancers14194919"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-4933-3-5","article-title":"A paradox of immunodeficiency and inflammation in human aging: Lessons learned from apoptosis","volume":"3","author":"Gupta","year":"2006","journal-title":"Immun. Ageing"},{"key":"ref_27","first-page":"75","article-title":"The relationship between diabetes mellitus and cancers and its underlying mechanisms","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2022-168723","article-title":"Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial","volume":"140","author":"Jones","year":"2022","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1182\/blood-2022-170859","article-title":"Survival of Patients with Multiple Myeloma Diagnosed with Second Primary Malignancies: An ASCO Cancerlinq Analysis","volume":"140","author":"Cooper","year":"2022","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","article-title":"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: Influence of thalidomide and lenalidomide during maintenance","volume":"120","author":"Usmani","year":"2012","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4359\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:32Z","timestamp":1760129072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":31,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174359"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174359","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}